Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 19;11(9):2645-2655.
doi: 10.7150/jca.40726. eCollection 2020.

Transcriptomic analysis reveals the oncogenic role of S6K1 in hepatocellular carcinoma

Keng Po Lai  1   2 , Angela Cheung  2 , Cheuk Hin Ho  2 , Nathan Yi-Kan Tam  2 , Jing Woei Li  2 , Xiao Lin  3 , Ting Fung Chan  3   4 , Nikki Pui-Yue Lee  5 , Rong Li  1
Affiliations

Transcriptomic analysis reveals the oncogenic role of S6K1 in hepatocellular carcinoma

Keng Po Lai et al. J Cancer. .

Abstract

The p70 ribosomal protein S6 kinase 1 (S6K1), a serine/threonine kinase, is commonly overexpressed in a variety of cancers. However, its expression level and functional roles in hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related death worldwide, is still largely unknown. In the current report, we show the in vivo and in vitro overexpression of S6K1 in HCC. In the functional analysis, we demonstrate that S6K1 is required for the proliferation and colony formation abilities in HCC. By using comparative transcriptomic analysis followed by gene ontology enrichment analysis and Ingenuity Pathway Analysis, we find that the depletion of S6K1 can elevate the expression of a cluster of apoptotic genes, tumor suppressor genes and immune responsive genes. Moreover, the knockdown of S6K1 is predicted to reduce the tumorigenicity of HCC through the regulation of hubs of genes including STAT1, HDAC4, CEBPA and ONECUT1. In conclusion, we demonstrate the oncogenic role of S6K1 in HCC, suggesting the possible use of S6K1 as a therapeutic target for HCC treatment.

Keywords: S6K1; hepatocellular carcinoma; proliferation; transcriptome; tumorigenicity.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
In vivo and in vitro overexpression of S6K1 in HCC. (A) copy-number-gain of S6K1 in human hepatocellular carcinoma. DNA copy-number variation of TCGA data is obtained from Oncomine (https://www.oncomine.org). (B) Overexpression of S6K1 transcript in a cohort of 80 HCC tumors (T) and paired adjacent non-tumoral livers (NT). (C) Upregulation of S6K1 in HCC cell lines, Hep3B, PLC5 and HepG2 as compared to the normal liver cell line L02. The mRNA expression level of S6K1 was determined by qRT-PCR. Data are presented as the mean ± SD values (***p = 0.0001, *p < 0.05).
Figure 2
Figure 2
Depletion of S6K1 suppresses in vitro proliferation of HCC cells. (A) Knockdown of S6K1 in HCC cell lines. qRT-PCR and western blotting demonstrated the knockdown efficiency of S6K1 in S6K1-depleted Hep3B, PLC5 and HepG2. (B-C) Depletion of S6K1 suppressed in vitro cell proliferation of HCC. The cell proliferation of S6K1-depleted cell line was determined by (B) WST-1 assay and (C) colony formation assay. Data are presented as the mean ± s.e.m. values (*p < 0.05).
Figure 3
Figure 3
Depletion of S6K1 reduces the proliferation and regains the apoptosis in HCC. (A) Gene-annotation enrichment analysis using The Database for Annotation, Visualization and Integrated Discovery (DAVID). Biological processes with p < 0.05 were considered statistically significant. (B) KEGG pathway analysis using DAVID.
Figure 4
Figure 4
Depletion of S6K1 regulates the gene network to suppress the tumor development.
Figure 5
Figure 5
Schematic diagram to summarize the oncogenic role of S6K1 in HCC.
Figure 6
Figure 6
Quantitative PCR analysis validates the result of transcriptome sequencing. The expression of tumor suppressor genes, apoptotic genes and cell proliferative genes were determined in S6K1-depleted HCC cell lines, as compared to shCtrl cells using qPCR. Data are presented as the mean ± s.e.m. values (*p < 0.05) (n = 8).
See this image and copyright information in PMC

References

    1. Liao H, Huang Y, Guo B. et al. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Am J Cancer Res. 2014;5:125–139. - PMC - PubMed
    1. Giannelli G, Rani B, Dituri F. et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut. 2014;63:1668–1676. - PubMed
    1. Lai KP, Chen J, He M. et al. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma. Int J Cancer. 2014;135:1790–1799. - PubMed
    1. Liu L, Dai Y, Chen J. et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3beta/Snail signaling. Hepatology. 2014;59:531–543. - PubMed
    1. Ma S, Lee TK, Zheng BJ. et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749–1758. - PubMed